GleamWall
中文EN

BHVN Biohaven Ltd.

Pharmaceutical Preparations · NYSE · SEC CIK 1935979 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY30.4%
TTM EPS YoY49.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA-161.3%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets137.3%
Debt / equity—
Current ratio3.05x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.87x
Accruals ratio-20.9%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense$635.07M$795.87M
SG&A expense$110.31M$89.24M
Operating income-$745.38M-$885.11M
Pretax income-$737.38M-$845.69M
Income tax$1.44M$735,000
Net income-$738.82M-$846.42M
EBITDA-$735.46M-$877.26M
EPS (basic)-6.86-9.28
EPS (diluted)-6.86-9.28
Weighted avg. shares (diluted)107.62M91.23M
Balance sheet
Cash & equivalents$229.96M$102.54M
Short-term investments$89.18M$386.86M
Current assets$368.33M$538.47M
PP&E, net$15.96M$17.32M
Goodwill$1.39M$1.39M
Intangibles$18.40M$18.40M
Total assets$451.45M$615.11M
Current liabilities$115.93M$154.23M
Total liabilities$399.38M$191.67M
Shareholders' equity$52.07M$423.44M
Shares outstanding132.78M101.22M
Cash flow statement
Operating cash flow-$609.44M-$582.45M
Capital expenditure$715,000$4.05M
Free cash flow-$610.15M-$586.50M
Investing cash flow$300.56M-$244.97M
Financing cash flow$439.12M$677.77M
Depreciation & amortization$9.92M$7.86M
Stock-based compensation$112.36M$71.96M

Free plan shows the latest 2 periods; Pro shows all 6 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.